P
Paul C. Anderson
Researcher at Boehringer Ingelheim
Publications - 36
Citations - 1608
Paul C. Anderson is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: HIV Protease Inhibitor & Protease. The author has an hindex of 17, co-authored 36 publications receiving 1567 citations. Previous affiliations of Paul C. Anderson include Merck & Co..
Papers
More filters
Journal ArticleDOI
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Daniel Lamarre,Paul C. Anderson,Murray D. Bailey,Pierre L. Beaulieu,Gordon Bolger,Pierre R. Bonneau,Michael Bös,Dale R. Cameron,Mireille Cartier,Michael G. Cordingley,Anne-Marie Faucher,Nathalie Goudreau,Stephen H. Kawai,George Kukolj,Lisette Lagacé,Steven R. LaPlante,Hans Narjes,Marc-André Poupart,Jean Rancourt,Roel E. Sentjens,Roger St. George,Bruno Simoneau,Gerhard G. Steinmann,Diane Thibeault,Youla S. Tsantrizos,Steven M. Weldon,Chan-Loi Yong,Montse Llinas-Brunet +27 more
TL;DR: Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor, illustrating the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.
Journal ArticleDOI
Practical, stereoselective synthesis of palinavir, a potent hiv protease inhibitor
Pierre L. Beaulieu,Pierre Lavallee,A. Abraham,Paul C. Anderson,Colette Boucher,Yves Bousquet,Jean-Simon Duceppe,James Gillard,Vida Gorys,Chantal Grand-Maître,Louis Grenier,Yvan Guindon,Ingrid Guse,Louis Plamondon,Francois Soucy,Serge Valois,and Dominik Wernic,Christiane Yoakim +17 more
TL;DR: A highly convergent and stereoselective synthesis which is amenable to the preparation of multikilogram quantities ofPalinavir, a potent peptidomimetic-based HIV protease inhibitor, is developed.
Journal ArticleDOI
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
Daniel Lamarre,G Croteau,Elizabeth Wardrop,Lise Bourgon,Diane Thibeault,C Clouette,M Vaillancourt,E Cohen,Christopher Pargellis,Christiane Yoakim,Paul C. Anderson +10 more
TL;DR: The results indicate that the antiviral activity of palinavir is specific to inhibition of the viral protease and occurs at a late stage in the replicative cycle of HIV-1.
Journal ArticleDOI
Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures
TL;DR: The crystal structure of HIV-2 protease in complex with a reduced amide inhibitor [BI-LA-398; Phe-Val-Phe-psi (CH2NH)-Leu-Glu-Ile-amide] has been determined and the shapes of the S1 and S2 pockets in the presence of this inhibitor are essentially unperturbed by the amino acid differences between HIV-1 and HIV- 2 proteases.